In contrast, overall survival for patients with SASH1 high expressing adenocarcinomas was associated with improved outcomes (Fig. 1G; HR (95% CI): 2.03 (1.47–2.8), p = 2.0 × 10–5 for low SASH1 versus high SASH1, log-rank p < 0.0001). Here, SASH1 is linked to adenocarcinoma.